{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1712",
  "slug": "resistant-infections-new-counterattack",
  "edition": "2026-11-18T00",
  "url": "https://hangingcontext.com/stories/2026-11-18/resistant-infections-new-counterattack/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Resistant and re-emerging infections are being met with phages and surveillance, not just new antibiotics.",
  "headline": "The bugs are outrunning the drugs. The counterattack is phages, maps and vaccines",
  "dek": "A phage cocktail that covers most drug-resistant Klebsiella, a new cholera phage, surging drug-resistant TB in Brazil and a returning pneumococcal strain in Catalonia.",
  "published_at": "2026-11-18T00:50:59Z",
  "labels": {
    "trust": "confirmed",
    "trust_text": "Confirmed · 4 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 4,
  "publishers": [
    "biorxiv-microbiology-amr-biosecurity",
    "medrxiv-epidemiology-public-health",
    "medrxiv-infectious-disease-surveillance"
  ],
  "sources": [
    "biorxiv-microbiology-amr-biosecurity",
    "medrxiv-epidemiology-public-health",
    "medrxiv-infectious-disease-surveillance"
  ],
  "distinct_source_count": 3,
  "key_facts": [
    {
      "text": "14 capsular types dominate drug-resistant Klebsiella circulation and account for 67-77% of the global burden; a repository of 48 lytic phages covers all 14, in a preprint.",
      "cites": [
        {
          "claim_ids": [
            "1794931618352060083",
            "1794931618353060084"
          ],
          "manifest_id": "1794929272793041218"
        }
      ],
      "self_reported": true
    },
    {
      "text": "MAA01, a new phage isolated from Haiti, has a 31,507 base-pair genome and 47 genes and reduces cholera bacterial load 4-fold in an infant mouse model, in a preprint.",
      "cites": [
        {
          "claim_ids": [
            "1794949648319518545",
            "1794949648323518547"
          ],
          "manifest_id": "1794949413124511466"
        }
      ],
      "self_reported": true
    },
    {
      "text": "Multidrug-resistant tuberculosis cases in Brazil grew 294% to 574% between 2017 and 2021 across high-risk populations, in a preprint.",
      "cites": [
        {
          "claim_ids": [
            "1794958617069733692"
          ],
          "manifest_id": "1794956379630601545"
        }
      ],
      "self_reported": true
    },
    {
      "text": "Pneumococcal serotype 14 reached 10.8% incidence in Catalonia in 2025, and only 18.8% of patients with serotype 14 disease were appropriately vaccinated, in a preprint.",
      "cites": [
        {
          "claim_ids": [
            "1794938642521395006",
            "1794938642536395008"
          ],
          "manifest_id": "1794938358482390807"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "What changed",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794931618352060083"
              ],
              "manifest_id": "1794929272793041218"
            },
            {
              "claim_ids": [
                "1794949648319518545"
              ],
              "manifest_id": "1794949413124511466"
            },
            {
              "claim_ids": [
                "1794958617069733692"
              ],
              "manifest_id": "1794956379630601545"
            },
            {
              "claim_ids": [
                "1794938642521395006"
              ],
              "manifest_id": "1794938358482390807"
            }
          ],
          "markdown": "Four papers describe the same problem from four directions: infections that drugs no longer reliably stop, and diseases that had receded coming back. The papers cover drug-resistant Klebsiella pneumoniae, cholera, multidrug-resistant tuberculosis in Brazil, and pneumococcal disease in Catalonia. Two of them propose phages, viruses that kill bacteria, as the countermeasure. The other two are surveillance: careful counts of what is actually circulating, and who it is hitting. All four are preprints, so none of the results has been peer reviewed."
        }
      ]
    },
    {
      "heading": "Phages, aimed by surveillance",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794931618352060083",
                "1794931618353060084",
                "1794931618354060085",
                "1794931618354060086"
              ],
              "manifest_id": "1794929272793041218"
            }
          ],
          "markdown": "The most developed countermeasure is a phage cocktail aimed at carbapenem-resistant Klebsiella pneumoniae. Fourteen capsular locus types dominate contemporary circulation of the resistant bacterium and account for 67 to 77% of the global burden, the paper reports. A repository of 48 lytic phages can be organized into capsule-defined modules to cover all 14 dominant types, and capsular typing alone is sufficient to assign effective phage modules, bypassing the need for isolate-level matching. That last point is the practical one: if the capsule type is enough to pick the treatment, a hospital does not need to match phages to each patient's isolate first. The paper also reports that the strain background had no significant effect on phage efficacy in 12 of 14 tested capsular types."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794949648319518545",
                "1794949648323518546",
                "1794949648323518547",
                "1794949648324518548"
              ],
              "manifest_id": "1794949413124511466"
            }
          ],
          "markdown": "A second phage paper reports a new bacteriophage, MAA01, isolated from Haiti, with a 31,507 base-pair genome and 47 genes. It targets the O1 lipopolysaccharide antigen of Vibrio cholerae, the bacterium that causes cholera, and it reduces the cholera bacterium's load by 4-fold in an infant mouse model. The paper notes a curiosity: MAA01 shows a virulent phenotype against Vibrio cholerae despite possessing a temperate genome. A mouse model is not a patient, and a fourfold reduction in bacterial load is a laboratory result, not a treatment, but a phage that works in a living animal is further along than one that only works in a dish."
        }
      ]
    },
    {
      "heading": "The old diseases are moving",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794958617069733692",
                "1794958617071733695",
                "1794958617072733697"
              ],
              "manifest_id": "1794956379630601545"
            },
            {
              "claim_ids": [
                "1794938642521395006",
                "1794938642529395007",
                "1794938642536395008"
              ],
              "manifest_id": "1794938358482390807"
            }
          ],
          "markdown": "The two surveillance papers are less encouraging. In Brazil, multidrug-resistant tuberculosis cases grew by 294% to 574% between 2017 and 2021 across high-risk populations. Treatment abandonment, coinfection, social vulnerability, and occupational exposure are the key determinants the authors identify for the spread, and they conclude that current public health policies in Brazil are insufficient to control multidrug-resistant tuberculosis in high-risk populations. In Catalonia, pneumococcal serotype 14 reached 10.8% incidence in 2025, driven by multiple established lineages, GPSC6, GPSC18, GPSC16 and GPSC39, rather than a novel clone, and 56.3% of patients with serotype 14 disease had comorbidities while only 18.8% were appropriately vaccinated."
        }
      ]
    },
    {
      "heading": "Why it matters",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794931618352060083",
                "1794931618354060085"
              ],
              "manifest_id": "1794929272793041218"
            },
            {
              "claim_ids": [
                "1794938642529395007",
                "1794938642536395008"
              ],
              "manifest_id": "1794938358482390807"
            },
            {
              "claim_ids": [
                "1794958617072733697"
              ],
              "manifest_id": "1794956379630601545"
            },
            {
              "claim_ids": [
                "1794949648323518547"
              ],
              "manifest_id": "1794949413124511466"
            }
          ],
          "markdown": "The four papers point in the same direction, and it is not toward a new antibiotic. The countermeasures on offer are knowledge: which capsule types dominate, which phage kills which bacterium, which lineages are circulating, and who is unvaccinated. The Klebsiella cocktail is designed around surveillance, with the capsule types chosen because they dominate circulation, and the Catalonia paper is explicit that the return of serotype 14 is a failure of protection, not the arrival of something new. The open question is whether phage cocktails can move from repositories and mouse models into hospitals at the speed the resistance numbers suggest they need to, and whether the surveillance findings change vaccination and treatment policy in the places the papers studied."
        }
      ]
    }
  ],
  "unresolved": [
    "All four papers are preprints; the phage results are preclinical and the surveillance counts have not been peer reviewed.",
    "Whether capsular typing alone works as well in hospitals as the Klebsiella paper's tests suggest is unproven in patients.",
    "The Brazil paper does not show what policy change would reverse the multidrug-resistant tuberculosis growth it reports."
  ],
  "decision_card": {
    "not_for": [
      "Anyone looking for an approved treatment — the phage results are preclinical and the papers are preprints"
    ],
    "useful_for": [
      "Health professionals tracking where the resistance response is actually being built",
      "Biotech readers following phage therapy from repository to clinic"
    ],
    "compare_against": [
      "New-antibiotic development as the default response to resistance",
      "Existing vaccination and TB control programmes in the regions studied"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-18T00"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794929272793041218",
    "1794949413124511466",
    "1794956379630601545",
    "1794938358482390807"
  ],
  "manifests": [
    {
      "title": "Capsular surveillance-guided phage cocktails against carbapenem-resistant Klebsiella pneumoniae",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.13.766362v1.full",
      "manifest_id": "1794929272793041218",
      "source_name": "biorxiv-microbiology-amr-biosecurity",
      "published_date": "2026-11-17"
    },
    {
      "title": "Emergence of a Novel Bacteriophage of Toxigenic Vibrio cholerae in Haiti",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.15.766889v1.full",
      "manifest_id": "1794949413124511466",
      "source_name": "biorxiv-microbiology-amr-biosecurity",
      "published_date": "2026-11-17"
    },
    {
      "title": "Multidrug-Resistant Tuberculosis Rates Among High-Risk Populations in Brazil: An Analysis from 2001 to 2021",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.15.26368155v1.full",
      "manifest_id": "1794956379630601545",
      "source_name": "medrxiv-epidemiology-public-health",
      "published_date": "2026-11-17"
    },
    {
      "title": "Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.16.26367621v1.full",
      "manifest_id": "1794938358482390807",
      "source_name": "medrxiv-infectious-disease-surveillance",
      "published_date": "2026-11-17"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794929272793041218",
      "1794949413124511466",
      "1794956379630601545",
      "1794938358482390807"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. Existing 72 Hour Agent Demo keys keep their issued limits. New keys require email OTP verification. An existing demo key lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794929272793041218",
      "all": "for id in 1794929272793041218 1794949413124511466 1794956379630601545 1794938358482390807; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-18/resistant-infections-new-counterattack/",
    "json": "https://hangingcontext.com/stories/2026-11-18/resistant-infections-new-counterattack/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-18/resistant-infections-new-counterattack/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-18T00/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/infection-tests-race-resistance/",
      "headline": "The infection test is catching up. The resistance is not waiting.",
      "slug": "infection-tests-race-resistance"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/",
      "headline": "Cancer's escape routes are getting named, one pathway at a time",
      "slug": "cancer-escape-routes-getting-named"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/blood-tests-split-speed-from-stage/",
      "headline": "One blood draw, two different answers about neurodegeneration",
      "slug": "blood-tests-split-speed-from-stage"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-20/drug-resistance-travels-in-chains/",
      "headline": "Drug resistance does not just appear — it travels, in chains you can now trace",
      "slug": "drug-resistance-travels-in-chains"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Run the cited Manifests yourself",
    "text": "Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. Existing 72 Hour Agent Demo keys keep their issued limits. New keys require email OTP verification. An existing demo key lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons.",
    "cta": {
      "label": "Get a key",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-18/resistant-infections-new-counterattack/"
  }
}
